The inhalation company Inhalation Sciences has received a large Inhalation Research Services (IRS) order from a global pharmaceutical company, according to a press release.The order is worth €224,555, corresponding to approximately SEK 2.45 million.The customer is a global pharmaceutical company with operations in over 100 countries. The assignment concerns advanced in vitro tests using the company's DissolvIt technology to compare several inhalation formulations in the early development phase."We are very pleased to have received this significant IRS order from a leading global pharmaceutical company. The project is an important confirmation of DissolvIt as a high-precision tool for comparing complex inhalation formulations in the preclinical phase, and the size and structure of the order, which includes multiple formulations and study phases, confirms the growing demand for sophisticated dissolution tests in the development of inhalation drugs," says Manoush Masarrat, CEO of Inhalation Sciences, in a comment.